Cited by Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality

CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity DOI

Mariela A. Moreno Ayala,

Timothy F. Campbell,

Chen‐Yu Zhang

et al.

Immunity, Journal Year: 2023, Volume and Issue: 56(7), P. 1613 - 1630.e5

Published: June 30, 2023

Language: Английский

Citations

105

Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity DOI

Siyuan You,

Shuqin Li,

Lingsu Zeng

et al.

Cancer Cell, Journal Year: 2024, Volume and Issue: 42(8), P. 1415 - 1433.e12

Published: July 18, 2024

Language: Английский

Citations

Cancer immune evasion, immunoediting and intratumour heterogeneity DOI

Malte Roerden, Stefani Spranger

Nature reviews. Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 2, 2025

Language: Английский

Citations

Mechanisms and Strategies of Immunosenescence Effects on Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Analysis and Future Directions DOI

Huatao Zhou,

Zilong Zheng,

Chengming Fan

et al.

Seminars in Cancer Biology, Journal Year: 2025, Volume and Issue: 109, P. 44 - 66

Published: Jan. 9, 2025

Language: Английский

Citations

Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back DOI

Annapaola Mariniello, Maxime Borgeaud, Marc Weiner

et al.

BioDrugs, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 15, 2025

Immunotherapy with checkpoint inhibitors has become the cornerstone of systemic treatment for non-oncogene addicted non-small-cell lung cancer. Despite its pivotal role, a significant proportion patients—approximately 70–85%—either exhibit primary resistance to PD-1 blockade or develop acquired following an initial benefit, even in combination chemotherapy and/or anti-CTLA-4 agents. The phenomenon and immunotherapy represents critical clinical challenge, largely based on our incomplete understanding mechanisms action immunotherapy, resulting lack accurate predictive biomarkers. Here, we review definitions explore proposed resistance, including those related tumor microenvironment, factors, intrinsic characteristics. We also discuss translational data adaptive changes within cells immune infiltrate exposure inhibitors. Lastly, offer comprehensive overview current emerging therapeutic strategies designed prevent counteract resistance.

Language: Английский

Citations

Same yet different — how lymph node heterogeneity affects immune responses DOI

Paulina Cruz de Casas, Konrad Knöpper, Rupak Dey Sarkar

et al.

Nature reviews. Immunology, Journal Year: 2023, Volume and Issue: 24(5), P. 358 - 374

Published: Dec. 14, 2023

Language: Английский

Citations

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors DOI

Camille Moeckel,

Katrina Bakhl,

Ilias Georgakopoulos-Soares

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(7), P. 6710 - 6710

Published: April 4, 2023

Cancer is one of the leading causes death in world; therefore, extensive research has been dedicated to exploring potential therapeutics, including immune checkpoint inhibitors (ICIs). Initially, programmed-death ligand-1 was biomarker utilized predict efficacy ICIs. However, its heterogeneous expression tumor microenvironment, which critical cancer progression, promoted exploration mutation burden (TMB). Research various cancers, such as melanoma and lung cancer, shown an association between high TMB response ICIs, increasing predictive value. failed ICI numerous other cancers. Therefore, future needed analyze variations types establish cutoffs order create a more standardized methodology for using clinically. In this review, we aim explore current on biomarker, discuss approaches overcoming immunoresistance highlight new trends field liquid biopsies, next generation sequencing, chimeric antigen receptor T-cell therapy, personalized vaccines.

Language: Английский

Citations

ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer DOI

Inês Mota, Enrico Patrucco, Cristina Mastini

et al.

Nature Cancer, Journal Year: 2023, Volume and Issue: 4(7), P. 1016 - 1035

Published: July 10, 2023

Language: Английский

Citations

Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors DOI

Lucía López, Luciano Gastón Morosi, Federica La Terza

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: March 13, 2024

Abstract Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T cell responses model antigens, in various tumor settings. However, the impact of cross-presenting cDC1 potential DC-based therapies tumors carrying varied levels bona-fide neoantigens (neoAgs) remain unclear. Here we develop a hypermutated non-small lung cancer female mice, encoding genuine MHC-I neoepitopes study neoAgs-specific spontaneous settings upon Flt3L + αCD40 (DC-therapy). We find that are required generate broad against range diverse neoAgs. DC-therapy promotes immunogenicity weaker neoAgs strongly inhibits growth high tumor-mutational burden (TMB) tumors. In contrast, low TMB respond poorly DC-therapy, generating mild not sufficient block progression. scRNA transcriptional analysis, immune profiling functional assays unveil changes induced tissues, which comprise accumulation with increased immunostimulatory properties less exhausted effector cells. conclude boosting activity broaden diversity anti-tumoral leverage content for therapeutic advantage.

Language: Английский

Citations

Lymphatic vessels in the age of cancer immunotherapy DOI

Triantafyllia Karakousi, Tenny Mudianto, Amanda W. Lund

et al.

Nature reviews. Cancer, Journal Year: 2024, Volume and Issue: 24(6), P. 363 - 381

Published: April 11, 2024

Language: Английский

Citations